[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-diseases-in-old-age\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-diseases-in-old-age":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,74,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100354486","noninvasive-elastography-evaluation-of-myocardial-stiffness-in-elderly-patients-with-isolated-diastolic-heart-failure-new-diagnostic-tool-100354486",false,"NCT03895541","Noninvasive Elastography Evaluation of Myocardial Stiffness in Elderly Patients With Isolated Diastolic Heart Failure: New Diagnostic Tool?","ELASTOCARDIO2","Global Inclusion Criteria:\n\n* Hospitalization in cardiology services for acute pulmonary edema during heart failure\n* Natriuretic peptide type B ≥35 pg\u002Fml\n* Echocardiographic structural alteration\n\nSpecific Inclusion criteria\n\n* Group \"preserved LVEF\": Left ventricular Ejection Fraction ≥50%\n* Group \"moderate alteration of LVEF\": Left ventricular Ejection Fraction between 40% and 49%\n* Group \"Systolic heart failure\": Left ventricular Ejection Fraction\\\u003C 40%\n\nGlobal Exclusion Criteria:\n\n* Other associated lung pathology\n* Other heart disease\n* Contraindication to MRI or echocardiography gel\n* Pregnancy\n* Poor echogenicity,","ALL","60 Years","80 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","The new approach propose in this protocol is based on ultrafast ultrasound and remote palpation of tissue by ultrasonic radiation pressure. Ultrafast ultrasound of biological tissues is based on an innovative ultrasound imaging approach that can image very fast soft tissue events at a rate of several thousands of frames per second and provide quantitative mapping of the elasticity of the tissues. This current project aims is to focus on myocardial rigidity in diastole to better assess the function of the heart failure.",[27],"Cardiovascular Diseases in Old Age",[29,30,31,32],"heart failure","myocardial rigidity","new diagnosis","ultrasound imaging","RECRUITING","2025-03-10",{"date":36,"type":37},"2025-03-11","ACTUAL",{"date":39,"type":37},"2020-01-24",{"date":41,"type":21},"2025-12-31",{"name":43,"class":44},"French Cardiology Society","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100486678","virtual-prehab-study-for-patients-undergoing-tavi-100486678","NCT05617196","Virtual PREHAB Study for Patients Undergoing TAVI","Feasibility of a Virtually Delivered Preoperative Rehabilitation Program for Patients Awaiting TAVI to Reduce Frailty: The Virtual PREHAB Study","Inclusion Criteria:\n\n* Outpatients attending the TAVI clinic at the Queen Elizabeth II Health Sciences Centre\n* Informed written or verbal consent\n\nExclusion Criteria:\n\n* New York Heart Association or Canadian Cardiovascular Score of 4\n* Severe functional limitations\n* Cognitive impairment that impacts consenting ability\n* Significant language barrier\n* No internet or telephone access that precludes virtual PREHAB participation","50 Years","100 Years",{"count":56,"type":21},40,[24],"Nova Scotians are aging and many are becoming frailer. People with frailty are more likely to live in worse health and do not recover well from major events, such as open heart surgery. Many people are also too frail to receive open heart surgery. Less invasive procedures called transcatheter aortic valve implantation, or TAVI, are provided for the frailest patients. While TAVI is life-saving, frailer patients are less likely to survive in better health after their operation. Patients in Nova Scotia can also wait up to 3-6 months for their operation where they become frailer or can die before receiving TAVI. The investigators believe that it is important to support these individuals to improve their frailty and overall health before their operation.\n\nCenter-based cardiac rehabilitation is offered to patients after, but not before TAVI to improve their health. Center-based preoperative cardiac rehabilitation (i.e., PREHAB) can safely improve the function of frail patients who received open heart surgery. However, many patients cannot come to a center-based PREHAB because of transportation requirements to access the program. Another option is to support these patients with virtually delivered PREHAB, where they can stay in their homes. However, this possibility has not been studied.\n\nFor this study, virtual PREHAB will be delivered using the virtual cardiac rehabilitation program in Nova Scotia to patients before TAVI. This intervention will be delivered by healthcare providers who routinely care for TAVI patients, including a medical director, program lead, nurse, physiotherapist, and dietician. Ther goal of this study is to determine if it is feasible and safe to use virtual PREHAB to reduce frailty before TAVI. This research fits with Research Nova Scotia's priorities to improve patient outcomes in those with significant long-term health conditions, and to provide accessible, safe, and quality virtual healthcare to patients so they can thrive after their operation.",[27,60,61],"Frailty","TAVI",[60,63,64,61],"Virtual PREHAB","Cardiac rehabilitation","2024-08-19",{"date":67,"type":37},"2024-08-21",{"date":69,"type":37},"2023-01-05",{"date":71,"type":21},"2025-12",{"name":73,"class":44},"Nova Scotia Health Authority",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":45},"100541915","metabolic-flexibility-and-autonomic-control-after-muscle-power-vs-metabolic-power-training-in-postmenopausal-oncological-women-the-power-health-study-100541915","NCT06336070","Metabolic Flexibility and Autonomic Control After Muscle Power vs Metabolic Power Training in Postmenopausal Oncological Women: the POWER Health Study","Postmenopausal Oncological Women Exercising for Recover Their Health. Associations and Changes in Metabolic Flexibility and Autonomic Control After Two Training Programs (Muscle Power vs Metabolic Power): the POWER Health Study","POWER Health","Inclusion Criteria:\n\n* Patients diagnosed of relapse free-cancer (RFC) or patients not diagnosed of any cancer at least the last 15 years (CG)\n* Aged between 35 and 75 years\n* Diagnostic of breast cancer (i.e., including ductal carcinoma, invasive carcinoma, triple negative; RFC) or physiological menopause (CG)\n* Not participating in a nutritional\u002Fdietary intervention\n* Not being physically active (i.e., not to be participating in any physical exercise program in the last 3 months, or performing less than 600 metabolic equivalents (METS)\u002Fweek of moderate-vigorous physical activity).\n* To be capable and willing to provide informed consent\n* Not to suffer from any specific condition that may impede testing of the study hypothesis or make it unsafe to engage in the exercise intervention (i.e., determined by the research staff).\n\nExclusion Criteria:\n\n* Medical contraindication for being engaged in an exercise.\n* Additional surgery planned within the intervention\n* Consuming usually betablocker or any drugs alterning nervous system functioning\n* History of another primary invasive cancer (RFC) or suffer a serious chronic illness (CG)\n* To present any of the following cardiac conditions: (i) myocardial infarction or coronary revascularization procedure within prior 3 months, (ii) uncontrolled hypertension (i.e., systolic ≥180 mmHg or diastolic ≥100 mmHg), (iii) uncontrolled arrhythmias (iv) valvular disease clinically significant, (v) decompensated heart failure or (vi) to suffer from known aortic aneurysm.","FEMALE","35 Years","75 Years",{"count":86,"type":21},56,[24],"POWER Health is a randomized clinical trial with a two-arm parallel design whose objectives are 1) to study metabolic flexibility and autonomic function (both capacities that describe cardiovascular health) in a sample of postmenopausal oncological women vs postmenopausal untreated controls (CT); and 2) to analyze the impact of two different 8-week physical exercise supervised interventions: HIIT training vs strength training focused on muscle power, on both cardiovascular capacities in these populations.",[90,91,92,93,27],"Breast Cancer Female","Cardiometabolic Syndrome","Metabolism Disorder, Lipid","Autonomic Dysfunction",[95,96,97,98,99,100,101,102,103,104,105,106],"Metabolic Flexibility","Heart Rate Variability","Muscle Power","Resting metabolic Rate","Lactate","High Intensity Interval Training","Strength Training","Breast Cancer","Ageing","Menopause","Female","Exercise Training","2024-04-02",{"date":109,"type":37},"2024-04-04",{"date":111,"type":37},"2024-01-01",{"date":113,"type":21},"2028-12-31",{"name":115,"class":44},"University of Valencia",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":124,"maxAge":4,"enrollmentInfo":125,"targetDuration":127,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":139,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":153},"100480463","tavis-registry---trilogy-heart-valve-system-for-management-of-patients-with-aortic-valve-disease-100480463","NCT05536310","TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease","Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease: Patient Registry and Post-Market Clinical Follow-up Study","TAVIS","Inclusion Criteria:\n\n1. Patients who have signed ICF and are indicated by their doctors to be treated with Trilogy Heart Valve System in line with the medical standard of care\n2. Patients with symptomatic severe aortic regurgitation (AR) or symptomatic, severe aortic stenosis (AS), who are at high risk for SAVR as documented by the heart team and Heart Team agrees that patient can undergo SAVR for \"bail out\"\u002Fto address unfavorable circumstances if necessary\n3. Patients 18 years of age or older\n4. Patient is willing to participate in the study, provides signed Informed Consent\u002FData Authorization Form and authorizes the sharing of data in the study\n5. The subject and treating physician agree the subject will return for all required post-procedure follow-up visits\n\nExclusion Criteria:\n\n1. Patients who have known hypersensitivity or contraindication to Nitinol (titanium and\u002For nickel), an anti-coagulation\u002Fanti-platelet regimen or contrast medium that cannot be managed with premedication\n2. Patients who have active bacterial endocarditis or other active infections\n3. Pediatric (\\\u003C18 years) and\u002For pregnant\u002Fnursing patients\n4. Congenital\u002Ffunctional unicuspid, bicuspid or quadricuspid native aortic valve morphology\n5. Previous prosthetic aortic valve (bioprosthesis or mechanical) implant\n6. Echocardiographic evidence of current left heart thrombus\n7. Hypertrophic cardiomyopathy with or without obstruction.\n8. Access vessel characteristics that would preclude safe placement of the JenaValve 20Fr introducer sheath, such as severe obstructive calcification, severe tortuosity, or vessel diameter \\\u003C7mm.","18 Years",{"count":126,"type":21},600,"5 Years","OBSERVATIONAL","To collect information about the management of symptomatic severe Aortic Stenosis (AS) and Aortic Regurgitation (AR) using transcatheter aortic valve replacement (TAVI).",[131,132,133,134,135,136,27,137,138],"Aortic Valve Stenosis","Aortic Valve Regurgitation","Aortic Valve Stenosis With Insufficiency","Constriction, Pathologic","Aortic Valve Disease","Heart Valve Diseases","Ventricular Outflow Obstruction","Aortic Stenosis, Severe",[140,135,141,132],"Trilogy","Transcatheter aortic valve replacement (TAVR)","NOT_YET_RECRUITING","2023-01-10",{"date":145,"type":37},"2023-01-11",{"date":147,"type":21},"2023-03",{"date":149,"type":21},"2027-10",{"name":151,"class":152},"JenaValve Technology, Inc.","INDUSTRY",3]